Porownywarka

BPC-157 vs TB-500 side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

BPC-157TB-500

Udostępnij porównanie peptydów

Wlasciwosc	BPC-157	TB-500
Kategoria	Regeneracja	Regeneracja
Znany tez jako	Body Protection Compound-157, Pentadecapeptide BPC 157	Thymosin Beta-4 fragment (LKKTETQ), Thymosin Beta-4, Fragment
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Phase 2 recruiting (NCT07437547); investigational. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical - No human clinical trials. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026) Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Injury recovery, gut healing, joint and tendon repair	Muscle recovery, wound healing, injury rehabilitation
Jak dziala	The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.	TB-500 is presented as a synthetic peptide based on the thymosin beta-4 active region. The supplied source identifies LKKTETQ, residues 17 to 23, as the short sequence commonly reproduced in TB-500 products and ties that region to G-actin binding. Through this actin-related pathway, thymosin beta-4 research connects cytoskeletal remodeling with cell migration into wound areas. The source also reports anti-inflammatory and pro-angiogenic activity in lab models. The main uncertainty is translational: evidence from full-length thymosin beta-4 does not prove that a 7-amino-acid fragment will reproduce the parent molecule's full biological profile.
Typowe dawkowanie	250-500 mcg twice daily · 1-2x daily	2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) · 2x weekly for 4-6 weeks, then 1x weekly
Dawkowanie z badań	250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic	2-2.5 mg twice weekly · 4-6 weeks loading, then maintenance · Subcutaneous or intramuscular injection
Typowy czas trwania	4-12 weeks in most research protocols	4-6 weeks loading, then maintenance
Podanie	Subcutaneous injection near injury site, or systemic	Subcutaneous or intramuscular injection
Timing	Morning and evening (or near injury site timing) With or without food	Morning or evening With or without food
Poziom dowodów	Badania kliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.) Nausea (Listed by the source without frequency or causality information.) Dizziness (Listed by the source without frequency or causality information.) +6 więcej Injection site reactions (Listed by the source without frequency or causality information.) Fatigue (Listed by the source without frequency or causality information.) Headache (Listed by the source without frequency or causality information.) May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.) Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.) Limited long-term human safety data (The source itself notes limited long-term human safety information.)	Generally well-tolerated in preclinical studies (Preclinical observation; long-term human safety data are limited.) Injection site reactions Headache +7 więcej Fatigue Nausea May trigger histamine release (Source advises caution for MCAS or histamine sensitivity.) Theoretical risk of facilitating tumor cell migration (Source notes thymosin beta-4 is upregulated in metastatic cancers.) Contraindicated with active cancer or cancer history (Source-supported contraindication note.) Limited long-term safety data WADA prohibited at all times (Listed in the source as prohibited on the 2025 WADA list.)
Podsumowanie researchu	According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.	The supplied research summary places TB-500 mainly in a preclinical evidence category and says most of the stronger evidence concerns full-length thymosin beta-4 rather than the TB-500 fragment. It reports animal findings in wound, scar, tendon, skin, and cardiac injury models. For human data, the source discusses RegeneRx programs using thymosin beta-4 forms: RGN-259 eye drops in a placebo-controlled Phase 3 neurotrophic keratopathy study, where corneal healing was reported in 6 of 10 treated patients versus 1 of 8 on placebo, and RGN-352 injection, which reached Phase 2 in a cardiac program before a manufacturing hold. These programs are not presented as human efficacy trials of the 7-amino-acid TB-500 fragment. For TB-500 as a fragment, the source states there are no completed, published human efficacy trials for muscle or tendon repair and mentions a recently listed cardiovascular biomarker study as early-stage.
Referencje	Źródło Źródło +2 więcej Źródło Źródło	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

BPC-157

TB-500

Kategoria

Regeneracja

Znany tez jako

Body Protection Compound-157, Pentadecapeptide BPC 157

Thymosin Beta-4 fragment (LKKTETQ), Thymosin Beta-4, Fragment

Zatwierdzony przez FDA

Nie

Status kliniczny

Phase 2 recruiting (NCT07437547); investigational.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical - No human clinical trials. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Injury recovery, gut healing, joint and tendon repair

Muscle recovery, wound healing, injury rehabilitation

Jak dziala

The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.

TB-500 is presented as a synthetic peptide based on the thymosin beta-4 active region. The supplied source identifies LKKTETQ, residues 17 to 23, as the short sequence commonly reproduced in TB-500 products and ties that region to G-actin binding. Through this actin-related pathway, thymosin beta-4 research connects cytoskeletal remodeling with cell migration into wound areas. The source also reports anti-inflammatory and pro-angiogenic activity in lab models. The main uncertainty is translational: evidence from full-length thymosin beta-4 does not prove that a 7-amino-acid fragment will reproduce the parent molecule's full biological profile.

Typowe dawkowanie

250-500 mcg twice daily · 1-2x daily

2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) · 2x weekly for 4-6 weeks, then 1x weekly

Dawkowanie z badań

250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic

2-2.5 mg twice weekly · 4-6 weeks loading, then maintenance · Subcutaneous or intramuscular injection

Typowy czas trwania

4-12 weeks in most research protocols

4-6 weeks loading, then maintenance

Podanie

Subcutaneous injection near injury site, or systemic

Subcutaneous or intramuscular injection

Timing

Morning and evening (or near injury site timing)

With or without food

Morning or evening

With or without food

Poziom dowodów

Badania kliniczne

Przedkliniczne

Mozliwe skutki uboczne

Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.)
Nausea (Listed by the source without frequency or causality information.)
Dizziness (Listed by the source without frequency or causality information.)

+6 więcej

Injection site reactions (Listed by the source without frequency or causality information.)
Fatigue (Listed by the source without frequency or causality information.)
Headache (Listed by the source without frequency or causality information.)
May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.)
Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.)
Limited long-term human safety data (The source itself notes limited long-term human safety information.)

Generally well-tolerated in preclinical studies (Preclinical observation; long-term human safety data are limited.)
Injection site reactions
Headache

+7 więcej

Fatigue
Nausea
May trigger histamine release (Source advises caution for MCAS or histamine sensitivity.)
Theoretical risk of facilitating tumor cell migration (Source notes thymosin beta-4 is upregulated in metastatic cancers.)
Contraindicated with active cancer or cancer history (Source-supported contraindication note.)
Limited long-term safety data
WADA prohibited at all times (Listed in the source as prohibited on the 2025 WADA list.)

Podsumowanie researchu

According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.

The supplied research summary places TB-500 mainly in a preclinical evidence category and says most of the stronger evidence concerns full-length thymosin beta-4 rather than the TB-500 fragment. It reports animal findings in wound, scar, tendon, skin, and cardiac injury models. For human data, the source discusses RegeneRx programs using thymosin beta-4 forms: RGN-259 eye drops in a placebo-controlled Phase 3 neurotrophic keratopathy study, where corneal healing was reported in 6 of 10 treated patients versus 1 of 8 on placebo, and RGN-352 injection, which reached Phase 2 in a cardiac program before a manufacturing hold. These programs are not presented as human efficacy trials of the 7-amino-acid TB-500 fragment. For TB-500 as a fragment, the source states there are no completed, published human efficacy trials for muscle or tendon repair and mentions a recently listed cardiovascular biomarker study as early-stage.

Referencje

+2 więcej

+2 więcej

Pełny profil